Modification of a loop sequence between α-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA α-helices 4 an

详细信息    查看全文

• 作者：Ayumu Kuroishi (1)
  Akatsuki Saito (2)
  Yasuhiro Shingai (1)
  Tatsuo Shioda (1)
  Masako Nomaguchi (3)
  Akio Adachi (3)
  Hirofumi Akari (2)
  Emi E Nakayama (1)
  
• 刊名：Retrovirology
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：6
• 期：1
• 全文大小：930KB
• 参考文献：1. Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A: Early replication block of human immunodeficiency virus type 1 in monkey cells. / J Gen Virol 1995, 76 (Pt 11) : 2723-730. CrossRef
  2. Himathongkham S, Luciw PA: Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. / Virology 1996, 219: 485-88. CrossRef
  3. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, Scammell J, Ferrigno P, Sodroski J: Species-specific, postentry barriers to primate immunodeficiency virus infection. / J Virol 1999, 73: 10020-0028.
  4. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A: Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. / J Virol 1991, 65: 3514-520.
  5. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. / Nat Med 2000, 6: 207-10. CrossRef
  6. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA: Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. / J Virol 2002, 76: 2123-130. CrossRef
  7. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. / Nat Med 1999, 5: 204-10. CrossRef
  8. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. / J Virol 1998, 72: 164-69.
  9. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. / Proc Natl Acad Sci USA 2000, 97: 2709-714. CrossRef
  10. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. / Nature 1988, 336: 484-87. CrossRef
  11. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. / Cell 2003, 113: 803-09. CrossRef
  12. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. / Nature 2003, 424: 99-03. CrossRef
  13. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. / Nature 2002, 418: 646-50. CrossRef
  14. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. / Cell 2003, 114: 21-1. CrossRef
  15. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. / Nat Med 2003, 9: 1398-403. CrossRef
  16. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. / Nat Med 2003, 9: 1404-407. CrossRef
  17. Goila-Gaur R, Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. / Retrovirology 2008, 5: 51. CrossRef
  18. Berthoux L, Sebastian S, Sokolskaja E, Luban J: Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. / J Virol 2004, 78: 11739-1750. CrossRef
  19. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM: Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. / Proc Natl Acad Sci USA 2003, 100: 1298-303. CrossRef
  20. Nakayama EE, Shingai Y, Kono K, Shioda T: TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells. / Virology 2008, 375: 514-20. CrossRef
  21. Kamada K, Igarashi T, Martin MA, Khamsri B, Hatcho K, Yamashita T, Fujita M, Uchiyama T, Adachi A: Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. / Proc Natl Acad Sci USA 2006, 103: 16959-6964. CrossRef
  22. Igarashi T, Iyengar R, Byrum RA, Buckler-White A, Dewar RL, Buckler CE, Lane HC, Kamada K, Adachi A, Martin MA: Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. / J Virol 2007, 81: 11549-1552. CrossRef
  23. Hatziioannou T, Princiotta M, Piatak M Jr, Yuan F, Zhang F, Lifson JD, Bieniasz PD: Generation of simian-tropic HIV-1 by restriction factor evasion. / Science 2006, 314: 95. CrossRef
  24. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. / Nature 2004, 427: 848-53. CrossRef
  25. Luban J: Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. / J Virol 2007, 81: 1054-061. CrossRef
  26. Towers GJ: The control of viral infection by tripartite motif proteins and cyclophilin A. / Retrovirology 2007, 4: 40. CrossRef
  27. Li Y, Li X, Stremlau M, Lee M, Sodroski J: Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. / J Virol 2006, 80: 6738-744. CrossRef
  28. Nakayama EE, Miyoshi H, Nagai Y, Shioda T: A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. / J Virol 2005, 79: 8870-877. CrossRef
  29. Ohkura S, Yap MW, Sheldon T, Stoye JP: All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. / J Virol 2006, 80: 8554-565. CrossRef
  30. Ozato K, Shin DM, Chang TH, Morse HC 3rd: TRIM family proteins and their emerging roles in innate immunity. / Nat Rev Immunol 2008, 8: 849-60. CrossRef
  31. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ: Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. / J Virol 2005, 79: 11580-1587. CrossRef
  32. Song H, Nakayama EE, Yokoyama M, Sato H, Levy JA, Shioda T: A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. / J Virol 2007, 81: 7280-285. CrossRef
  33. Adachi A, Gendelman HE, Koeing S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. / J Virol 1986, 59: 284-91.
  34. Kono K, Song H, Shingai Y, Shioda T, Nakayama EE: Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection. / Virology 2008, 373: 447-56. CrossRef
  35. Akari H, Mori K, Terao K, Otani I, Fukasawa M, Mukai R, Yoshikawa Y: In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses. / Virology 1996, 218: 382-88. CrossRef
  36. Miyoshi H, Takahashi M, Gage FH, Verma IM: Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. / Proc Natl Acad Sci USA 1997, 94: 10319-0323. CrossRef
  37. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM: Development of a self-inactivating lentivirus vector. / J Virol 1998, 72: 8150-157.
  38. Akari H, Fukumori T, Iida S, Adachi A: Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86. / Biochem Biophys Res Commun 1999, 263: 352-56. CrossRef
  39. Lin TY, Emerman M: Cyclophilin A interacts with diverse lentiviral capsids. / Retrovirology 2006, 3: 70. CrossRef
  40. Besnier C, Takeuchi Y, Towers G: Restriction of lentivirus in monkeys. / Proc Natl Acad Sci USA 2002, 99: 11920-1925. CrossRef
  41. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD: Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. / Proc Natl Acad Sci USA 2002, 99: 11914-1919. CrossRef
  42. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ: Restriction of multiple divergent retroviruses by Lv1 and Ref1. / Embo J 2003, 22: 385-94. CrossRef
  43. Maegawa H, Nakayama EE, Kuroishi A, Shioda T: Silencing of tripartite motif protein (TRIM) 5alpha mediated anti-HIV-1 activity by truncated mutant of TRIM5alpha. / J Virol Methods 2008, 151: 249-56. CrossRef
  44. Lin TY, Emerman M: Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. / Virology 2008, 379: 335-41. CrossRef
  45. Hatziioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD: A macaque model of HIV-1 infection. / Proc Natl Acad Sci USA 2009, 106: 4425-429. CrossRef
  46. Kuang YQ, Tang X, Liu FL, Jiang XL, Zhang YP, Gao G, Zheng YT: Genotyping of TRIM5 locus in northern pig-tailed macaques (Macaca leonina), a primate species susceptible to Human Immunodeficiency Virus type 1 infection. / Retrovirology 2009, 6: 58. CrossRef
  47. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T: Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. / Proc Natl Acad Sci USA 2008, 105: 3563-568. CrossRef
  48. Brennan G, Kozyrev Y, Kodama T, Hu SL: Novel TRIM5 isoforms expressed by Macaca nemestrina. / J Virol 2007, 81: 12210-2217. CrossRef
  
• 作者单位：Ayumu Kuroishi (1)
  Akatsuki Saito (2)
  Yasuhiro Shingai (1)
  Tatsuo Shioda (1)
  Masako Nomaguchi (3)
  Akio Adachi (3)
  Hirofumi Akari (2)
  Emi E Nakayama (1)
  
  1. Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, 565-0871, Osaka, Japan
  2. Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 305-0843, Ibaraki, Japan
  3. Department of Virology, Institute of Health Biosciences, University of Tokushima Graduate School, 770-8503, Tokushima, Japan
  
• ISSN：1742-4690

文摘

Background Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and chimpanzees but not cynomolgus or rhesus monkeys while simian immunodeficiency virus isolated from macaque (SIVmac) readily establishes infection in those monkeys. Several HIV-1 and SIVmac chimeric viruses have been constructed in order to develop an animal model for HIV-1 infection. Construction of an HIV-1 derivative which contains sequences of a SIVmac239 loop between α-helices 4 and 5 (L4/5) of capsid protein (CA) and the entire SIVmac239 vif gene was previously reported. Although this chimeric virus could grow in cynomolgus monkey cells, it did so much more slowly than did SIVmac. It was also reported that intrinsic TRIM5α restricts the post-entry step of HIV-1 replication in rhesus and cynomolgus monkey cells, and we previously demonstrated that a single amino acid in a loop between α-helices 6 and 7 (L6/7) of HIV type 2 (HIV-2) CA determines the susceptibility of HIV-2 to cynomolgus monkey TRIM5α. Results In the study presented here, we replaced L6/7 of HIV-1 CA in addition to L4/5 and vif with the corresponding segments of SIVmac. The resultant HIV-1 derivatives showed enhanced replication capability in established T cell lines as well as in CD8+ cell-depleted primary peripheral blood mononuclear cells from cynomolgus monkey. Compared with the wild type HIV-1 particles, the viral particles produced from a chimeric HIV-1 genome with those two SIVmac loops were less able to saturate the intrinsic restriction in rhesus monkey cells. Conclusion We have succeeded in making the replication of simian-tropic HIV-1 in cynomolgus monkey cells more efficient by introducing into HIV-1 the L6/7 CA loop from SIVmac. It would be of interest to determine whether HIV-1 derivatives with SIVmac CA L4/5 and L6/7 can establish infection of cynomolgus monkeys in vivo.